Natural History Study of Usher Syndrome ( Light4Deaf )
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- This is an observational study: the protocol does not assign a study treatment.
- Who it may be relevant to
- Registry conditions: Usher Syndromes. Basic parameters: No limits · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- France
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Natural History Study of Usher Syndrome in a Cohort of Patients Followed Longitudinally for 5 Years
Overview
Clinical centres in the LIGHT4DEAF consortium have developed and will continue to improve a reliable, early molecular diagnosis and protocols for full clinical characterisation of Usher syndrome, which will be valuable for the foreseen USH clinical trials. The clinical arm of the project aims at performing a deep-phenotyping of retinal degeneration, hearing loss, vestibular dysfunction, neurocognitive ability of subects with a molecular diagnosis of any Usher syndrome. Functional and structural parameters for retinal, auditory, and vestibular impairments are followed overtime to document the natural history of the disease and establish relevant clinical endpoint for disease progression that may be useful for future clinical trials.
Detailed description
Our cohort study aims at precisely documenting ophthalmic, auditory, vestibular, cogninitive alterations over time with phenotype/genotype correlation Ophthalmological assessment; Best corrected visual acuity, kynetic perimetry, microperimetry, colour contrast sensitivity, retinal multimodal imaging (fundus photograph, fundus autofluorescence, SD-OCT, OCTA, adaptive optics)
ENT assessment:
Tone and voice audiometry, Distortion product otoacoustic emissions Language assessment for children
Vestibular assessment:
Complete assessment of vestibular, canal and otolithic function Neuro-cognitive and visio spatial assessment Genetic: deep-genotyping using next generation sequencing
Primary outcome measures
- 5-year natural history of Usher syndrome [Time frame: From date of inclusion until the date of last documented progression , assessed up to 5 years]
Eligibility criteria
Inclusion criteria
- Patient with a molecular diagnosis of Usher syndrome type I, II or III or a clinical diagnosis of Usher syndrome type I, II or III which will then be confirmed by a molecular diagnosis
- Health insurance beneficiary
- Informed consent signed by the patient or their legal representatives
Exclusion criteria
- Patient or his/her legal representatives unable to understand the study and for whom informed consent cannot be obtained
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
France · 4 centers
- Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts — Paris
- CHU Pitié Salpêtrière — Paris
- CHU Necker — Paris
- CHU Robert Debré — Paris
Identifiers
NCT: NCT04665726 · P16-05 · 2016-A01715-46